Executive brief
FDA Cybersecurity Guidance is no longer something life sciences and medical device companies can treat as background reading. It is now shaping how manufacturers design products, document controls, validate systems, manage vulnerabilities, and prepare regulatory submissions. As connected devices, cloud systems, software components, and AI-enabled functions become more common, FDA expectations around cybersecurity have become more explicit and more consequential.
For medical device companies especially, the shift is direct and enforceable. As outlined in Understanding FD&C 524B – Cybersecurity Requirements for Medical Devices, the FDA can now refuse certain submissions that do not meet cybersecurity requirements tied to Section 524B of the FD&C Act. That changes cybersecurity from a best practice into a market access issue.
At its core, FDA Cybersecurity Guidance is telling manufacturers to stop treating cybersecurity as an afterthought. Security cannot be bolted on at the end of development or addressed only when an auditor asks for evidence. It has to be built into product design, software architecture, supplier oversight, testing, release management, and postmarket operations.
That message has been building for years, and USDM traces that evolution clearly in Cybersecurity in Medical Devices: How Did 524B Come About?, which shows how the FDA moved from recommendations toward enforceable cybersecurity expectations for medical devices.
Although the details vary by device and submission type, several themes run through current FDA expectations. Organizations need to demonstrate that they understand the cybersecurity risk of their products and systems, that they can document the controls in place, and that they have a credible plan to monitor and respond to vulnerabilities over time.
Secure product design and cybersecurity risk management throughout the lifecycle
Software component visibility, including software bills of materials where required